![Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2119136921/2089647169/gr1.gif)
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology
![Drug giants threaten NHS with legal action over cheaper drug that could save £84m a year | NHS | The Guardian Drug giants threaten NHS with legal action over cheaper drug that could save £84m a year | NHS | The Guardian](https://i.guim.co.uk/img/media/3d3e9775df68e1820a08c6aff889a11d0224fec4/0_66_3000_1800/master/3000.jpg?width=1200&height=630&quality=85&auto=format&fit=crop&overlay-align=bottom%2Cleft&overlay-width=100p&overlay-base64=L2ltZy9zdGF0aWMvb3ZlcmxheXMvdGctYWdlLTIwMTcucG5n&s=c746753b4b42404a2bea7edbffb28f53)
Drug giants threaten NHS with legal action over cheaper drug that could save £84m a year | NHS | The Guardian
![Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial - The Lancet Oncology Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/45ac9b4d-19f2-4935-92d8-deac0f5f9e89/gr1_lrg.gif)
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial - The Lancet Oncology
![Novartis' new macular degeneration drug has to compete against colon cancer drug Avastin. Why? < Pharma < 기사본문 - KBR Novartis' new macular degeneration drug has to compete against colon cancer drug Avastin. Why? < Pharma < 기사본문 - KBR](http://cdn.koreabiomed.com/news/photo/201904/5588_5614_4157.jpg)
Novartis' new macular degeneration drug has to compete against colon cancer drug Avastin. Why? < Pharma < 기사본문 - KBR
![Genentech: Statements | Genentech Statement on Counterfeit Drug Labeled as Avastin® (Bevacizumab) in the United States Genentech: Statements | Genentech Statement on Counterfeit Drug Labeled as Avastin® (Bevacizumab) in the United States](https://www.gene.com/assets/frontend/img/content/avastin-fake.png)